

NCT02652572 Raw comparison:

Summary:
CHIA has 38 criteria while your personal folder has 39 criteria
Total found criteria: 38/38
Total not Found: 0/38
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Age 18 years or older                              │ Age 18 years or older                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of venous leg ulcer(s) as clinically     │ Diagnosis of venous leg ulcer(s) as clinically     │
│ determined by the investigator by a positive       │ determined by the investigator by a positive       │
│ venous reflux test (venous refilling <20 seconds)  │ venous reflux test (venous refilling \<20 seconds) │
│ using Doppler ultrasound for at least 4 weeks      │ using Doppler ultrasound for at least 4 weeks      │
│ prior to screening day which have not adequately   │ prior to screening day which have not adequately   │
│ responded to conventional ulcer therapy            │ responded to conventional ulcer therapy            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Designated venous leg ulcer meets the following    │ Designated venous leg ulcer meets the following    │
│ criteria at both the screening and baseline visits │ criteria at both the screening and baseline visits │
│ If the patient has multiple ulcers at least one    │ If the patient has multiple ulcers at least one    │
│ ulcer must meet the following criteria at both the │ ulcer must meet the following criteria at both the │
│ screening and baseline visits                      │ screening and baseline visits                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Present for at least 4 weeks                       │ Present for at least 4 weeks                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ CEAP Classification Stage 6                        │ CEAP Classification Stage 6                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Surface ulcer with an area > 15cm2 post            │ Surface ulcer with an area \> 15cm2 post           │
│ debridement                                        │ debridement                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Viable granulating wound (investigator discretion) │ Viable granulating wound (investigator discretion) │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ulcers that extend through the epidermis but not   │ Ulcers that extend through the epidermis but not   │
│ through the muscle tendon or bone (Stage II or III │ through the muscle tendon or bone (Stage II or III │
│ ulcers as defined by the IAET)                     │ ulcers as defined by the IAET)                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female patients of childbearing potential must     │ Female patients of childbearing potential must     │
│ have a negative pregnancy test at screening and    │ have a negative pregnancy test at screening and    │
│ must agree to use hormonal contraceptive           │ must agree to use hormonal contraceptive           │
│ intrauterine device diaphragm with spermicide      │ intrauterine device diaphragm with spermicide      │
│ condom with spermicide or abstinence throughout    │ condom with spermicide or abstinence throughout    │
│ until 2 weeks after the last administration of     │ until 2 weeks after the last administration of     │
│ study drug                                         │ study drug                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Signed informed consent                            │ Signed informed consent                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Decrease in size of the designated target ulcer(s) │ Decrease in size of the designated target ulcer(s) │
│ by ≥ 30% during the 7-day screening period         │ by ≥ 30% during the 7-day screening period         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cannot tolerate or comply with compression therapy │ Cannot tolerate or comply with compression therapy │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ An ulcer which shows signs of severe clinical      │ An ulcer which shows signs of severe clinical      │
│ infection defined as pus oozing from the ulcer     │ infection defined as pus oozing from the ulcer     │
│ site                                               │ site                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ An ulcer positive for β-hemolytic streptococci     │ An ulcer positive for β-hemolytic streptococci     │
│ upon culture                                       │ upon culture                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The ulcer has > 50% slough significant necrotic    │ The ulcer has \> 50% slough significant necrotic   │
│ tissue bone tendon or capsule exposure or          │ tissue bone tendon or capsule exposure or          │
│ avascular ulcer beds                               │ avascular ulcer beds                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Is highly exuding (i e requires daily change of    │ Is highly exuding (i e requires daily change of    │
│ dressing)                                          │ dressing)                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ankle brachial pressure index <0 65                │ Ankle brachial pressure index \<0 65               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with active systemic infections           │ Patients with active systemic infections           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with clinically significant medical       │ Patients with clinically significant medical       │
│ conditions as determined by the investigator       │ conditions as determined by the investigator       │
│ including renal hepatic hematologic neurologic or  │ including renal hepatic hematologic neurologic or  │
│ immune disease Examples include but are not        │ immune disease Examples include but are not        │
│ limited to                                         │ limited to                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Renal insufficiency as an estimated GFR which is < │ Renal insufficiency as an estimated GFR which is   │
│ 30 mL/min/1 7m2                                    │ \< 30 mL/min/1 7m2                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Abnormal blood biochemistry defined as 3 times     │ Abnormal blood biochemistry defined as 3 times     │
│ that of the upper limit of the normal range        │ that of the upper limit of the normal range        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hepatic insufficiency defined as total bilirubin > │ Hepatic insufficiency defined as total bilirubin   │
│ 2 mg/dL or serum albumin < 25 g/L                  │ \> 2 mg/dL or serum albumin \< 25 g/L              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HbA1c > 9%                                         │ HbA1c \> 9%                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin < 10 g/dL                               │ Hemoglobin \< 10 g/dL                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hematocrit < 0 30                                  │ Hematocrit \< 0 30                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count < 100 000                           │ Platelet count \< 100 000                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of an active systemic or local cancer or  │ Presence of an active systemic or local cancer or  │
│ tumor of any kind (with the exception of non-      │ tumor of any kind (with the exception of non-      │
│ melanoma skin cancer)                              │ melanoma skin cancer)                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with severe rheumatoid arthritis (with    │ Patients with severe rheumatoid arthritis (with    │
│ more than 20 persistently inflamed joints or below │ more than 20 persistently inflamed joints or below │
│ lower normal limit blood albumin level or evidence │ lower normal limit blood albumin level or evidence │
│ of bone and cartilage damage on x-ray or           │ of bone and cartilage damage on x-ray or           │
│ inflammation in tissues other than joints) and     │ inflammation in tissues other than joints) and     │
│ other collagen vascular diseases                   │ other collagen vascular diseases                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with active connective tissue disease     │ Patients with active connective tissue disease     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with systemic corticosteroids (>15       │ Treatment with systemic corticosteroids (\>15      │
│ mg/day) or current immunosuppressive agents        │ mg/day) or current immunosuppressive agents        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous or current radiation therapy or           │ Previous or current radiation therapy or           │
│ likelihood to receive this therapy during study    │ likelihood to receive this therapy during study    │
│ participation                                      │ participation                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or nursing patients                       │ Pregnant or nursing patients                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known prior inability or unavailability to         │ Known prior inability or unavailability to         │
│ complete required study visits during study        │ complete required study visits during study        │
│ participation                                      │ participation                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant peripheral edema as per investigator's │ Significant peripheral edema as per investigator's │
│ discretion                                         │ discretion                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A psychiatric condition (e g suicidal ideation) or │ A psychiatric condition (e g suicidal ideation) or │
│ chronic alcohol or drug abuse problem determined   │ chronic alcohol or drug abuse problem determined   │
│ from the patient's medical history which in the    │ from the patient's medical history which in the    │
│ opinion of the investigator may pose a threat to   │ opinion of the investigator may pose a threat to   │
│ patient compliance                                 │ patient compliance                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of a platelet-derived growth factor within 28  │ Use of a platelet-derived growth factor within 28  │
│ days before screening                              │ days before screening                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any investigational drug or therapy within  │ Use of any investigational drug or therapy within  │
│ 28 days before screening                           │ 28 days before screening                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has any other factor which may in the opinion of   │ Has any other factor which may in the opinion of   │
│ the investigator compromise participation and/or   │ the investigator compromise participation and/or   │
│ follow-up in the study                             │ follow-up in the study                             │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛